Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer
Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer
复制标题
DOI：
10.1200/jco.2014.58.6842
复制
发表时间：
2015-04-01
影响因子：
45.3
通讯作者：
Chlebowski, Rowan T.
中科院分区：
文献类型：
--
作者：
Newcomb, Polly A.;Passarelli, Michael N.;Chlebowski, Rowan T.
目的双膦酸盐是治疗骨质疏松症的常用药物，也用于减少癌症患者的骨转移。包括妇女健康倡议（WHI）在内的几项研究发现，使用双膦酸盐与降低患乳腺癌的风险有关，但对与其他常见恶性肿瘤的关系知之甚少。这项研究的目的是检查双磷酸盐对子宫内膜癌风险的影响。方法我们在参加WHI的89，918名绝经后妇女队列中评估了口服双磷酸盐与子宫内膜癌风险之间的关系。在基线时进行详细的健康访谈，并从基线和随访时经常使用的药物清单中确定双膦酸盐的使用。所有妇女有一个完整的子宫在研究entry.ResultsDuring中位随访12.5年，1,123名妇女被诊断为偶发浸润性子宫内膜癌。曾经使用过双膦酸盐与子宫内膜癌风险降低相关（调整后的风险比，0.80; 95%CI，0.64至1.00; P = 0.05），与年龄，体重指数，或indicationforuse.ConclusionIn这个大的前瞻性队列绝经后妇女，双膦酸盐的使用与子宫内膜癌风险的统计学显着降低。(C)2015年美国临床肿瘤学会
PurposeBisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer.MethodsWe evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry.ResultsDuring a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use.ConclusionIn this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk. (C) 2015 by American Society of Clinical Oncology